33 related articles for article (PubMed ID: 11204021)
1. Prophylactic use of the anti-IL-2 receptor monoclonal antibody LO-Tact-1 in cadaveric renal transplantation: results of a randomized study.
Kriaa F; Hiesse C; Alard P; Lantz O; Noury J; Charpentier B; Bazin H
Transplant Proc; 1993 Feb; 25(1 Pt 1):817-9. PubMed ID: 8438496
[No Abstract] [Full Text] [Related]
2. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy.
Lietz K; John R; Beniaminovitz A; Burke EM; Suciu-Foca N; Mancini DM; Edwards NM; Itescu S
Transplantation; 2003 Mar; 75(6):781-7. PubMed ID: 12660501
[TBL] [Abstract][Full Text] [Related]
3. Is there any role for antithymocyte induction in renal transplantation?
Neidlinger NA; Sollinger HW
Transplant Proc; 2010 Jun; 42(5):1402-7. PubMed ID: 20620444
[TBL] [Abstract][Full Text] [Related]
4. Anti-interleukin 2 receptor monoclonal antibody therapy in rat recipients of cardiac allografts: the role of antibody isotype.
Kupiec-Weglinski JW; Di Stefano R; Stunkel KG; Grutzmann R; Theisen P; Araneda D; Tilney NL; Diamantstein T
Transplant Proc; 1988 Feb; 20(1 Suppl 1):272-5. PubMed ID: 3126574
[No Abstract] [Full Text] [Related]
5. Selection and chimerization of a monoclonal CD4 antibody for heart transplantation.
Reiter C; Meiser BM; Uberfuhr P; Wenke K; Reichenspurner H; Kreuzer E; Rieber EP; Riethmüller G; Reichart B
Transplant Proc; 1993 Feb; 25(1 Pt 1):788-9. PubMed ID: 8438481
[No Abstract] [Full Text] [Related]
6. [Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody].
Campana C
Ital Heart J Suppl; 2000 Jun; 1(6):838-9. PubMed ID: 11204021
[No Abstract] [Full Text] [Related]
7. New advances in antirejection therapy.
Chan M; Pearson GJ
Curr Opin Cardiol; 2007 Mar; 22(2):117-22. PubMed ID: 17284990
[TBL] [Abstract][Full Text] [Related]
8. [Small bowel transplantation].
Fukuzawa M
Nihon Rinsho; 2005 Apr; 63 Suppl 4():685-9. PubMed ID: 15861729
[No Abstract] [Full Text] [Related]
9. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Waldmann TA
J Clin Immunol; 2007 Jan; 27(1):1-18. PubMed ID: 17216565
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2 receptor antagonists as induction therapy after heart transplantation: systematic review with meta-analysis of randomized trials.
Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
J Heart Lung Transplant; 2008 Aug; 27(8):835-42. PubMed ID: 18656795
[TBL] [Abstract][Full Text] [Related]
11. [Advances in immunossuppression in liver transplantation].
Olivera-Martínez MA
Rev Invest Clin; 2005; 57(2):237-43. PubMed ID: 16524064
[TBL] [Abstract][Full Text] [Related]
12. Clinical advances in therapies targeting the interleukin-2 receptor.
Church AC
QJM; 2003 Feb; 96(2):91-102. PubMed ID: 12589007
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
